Pregled bibliografske jedinice broj: 1253558
Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin- Timolol Combination: A Prospective Real-Life Study
Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin- Timolol Combination: A Prospective Real-Life Study // Clinical Ophthalmology, 16 (2022), 3181-3192 doi:10.2147/opth.s382497 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1253558 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Tolerability in Glaucoma Patients Switched from
Preserved to Preservative-Free Prostaglandin-
Timolol Combination: A Prospective Real-Life Study
Autori
Jandroković, Sonja ; Vidas Pauk, Sania ; Lešin Gaćina, Dina ; Škegro, Ivan ; Tomić, Martina ; Masnec, Sanja ; Kuzman, Tomislav ; Kalauz, Miro
Izvornik
Clinical Ophthalmology (1177-5483) 16
(2022);
3181-3192
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
benzalkonium chloride ; fixed combinations ; glaucoma ; preservative ; preservative-free ; prostaglandin analogs
Sažetak
Purpose: To evaluate the effect of switching from preserved prostaglandin analog-timolol fixed combinations (PG-timolol FCs) to preservative-free latanoprost-timolol FC (PF-LT) on intraocular pressure (IOP), ocular surface health, and tolerability in glaucoma and ocular hypertension (OH) patients with the concurrent ocular surface disease (OSD). Methods: This was a longitudinal, prospective, interventional, real-life study among 42 patients. Up to 3 visits were planned, at baseline, 30, and 90 days to assess efficacy on IOP decrease and local tolerance. The severity of OSD symptoms [Ocular Surface Disease Index (OSDI) questionnaire], subjective drug tolerability [visual analog scale (VAS)], conjunctival hyperemia (McMonnies scale), and tear break-up time (TBUT) were the main parameters assessed. Results: Data from 36 patients were available for statistical analysis. IOP was significantly reduced at day 30 and day 90 compared to baseline (16 vs 14 vs 14 mmHg, p < 0.001). Significant improvement was demonstrated in OSD symptoms, signs, and VAS scores from the baseline to the second and third visits. Median OSDI (27.1 vs 9.6 vs 4.2, p < 0.001), conjunctival hyperemia (2 vs 1 vs 1, p < 0.001), corneal surface staining (p < 0.001), and conjunctival staining scores (p < 0.001), and the percentage of patients with eyelid and periocular hyperemia (61.1 vs 12.5 vs 2.8%, p < 0.001), significantly decreased. TBUT (4 vs 5 vs 6 s, p < 0.001) and VAS score regarding tolerability (5 vs 2 vs 1, p < 0.001) significantly increased. Conclusion: A switch from preserved PG-timolol FCs to PF-LT improved tolerability and optimized IOP control, providing better adherence with greater chances of treatment success. Keywords: benzalkonium chloride ; fixed combinations ; glaucoma ; preservative ; preservative-free ; prostaglandin analogs.
Izvorni jezik
Engleski
Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
Napomena
Sonja Jandroković, Sania Vidas Pauk, Dina Lešin Gaćina, Ivan Skegro, Sanja Masnec and
Tomislav Kuzman reports grants from Laboratoires Théaaffiliate Inspharma, during the
conduct of the study. The authors report no conflicts of interest regarding this work.
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur",
Klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
IVAN ŠKEGRO
(autor)
Martina Tomić
(autor)
Sonja Jandroković
(autor)
Tomislav Kuzman
(autor)
Miro Kalauz
(autor)
SANJA MASNEC
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)
- Scopus